BONE BIOLOGICS CORP (BBLG) Stock Price & Overview

NASDAQ:BBLG • US0980706008

Current stock price

1.16 USD
0 (0%)
Last:

The current stock price of BBLG is 1.16 USD. Today BBLG is down by 0%. In the past month the price decreased by -3.33%. In the past year, price decreased by -78.03%.

BBLG Key Statistics

52-Week Range1.11 - 6.75
Current BBLG stock price positioned within its 52-week range.
1-Month Range1.14 - 1.36
Current BBLG stock price positioned within its 1-month range.
Market Cap
2.088M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-3.76
Dividend Yield
N/A

BBLG Stock Performance

Today
0%
1 Week
-4.92%
1 Month
-3.33%
3 Months
-36.61%
Longer-term
6 Months -45.02%
1 Year -78.03%
2 Years -90.92%
3 Years -99.69%
5 Years N/A
10 Years N/A

BBLG Stock Chart

BONE BIOLOGICS CORP / BBLG Daily stock chart

BBLG Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to BBLG. When comparing the yearly performance of all stocks, BBLG is a bad performer in the overall market: 96.03% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

BBLG Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to BBLG. BBLG has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BBLG Earnings

Next Earnings DateMay 11, 2026
Last Earnings DateMar 2, 2026
PeriodQ4 / 2025
EPS Reported-$0.14
Revenue Reported
EPS Surprise 59.63%
Revenue Surprise %

BBLG Forecast & Estimates

7 analysts have analysed BBLG and the average price target is 22.7 USD. This implies a price increase of 1856.47% is expected in the next year compared to the current price of 1.16.


Analysts
Analysts82.86
Price Target22.7 (1856.9%)
EPS Next Y63.11%
Revenue Next YearN/A

BBLG Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

BBLG Financial Highlights

Over the last trailing twelve months BBLG reported a non-GAAP Earnings per Share(EPS) of -3.76. The EPS increased by 87.38% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-3.11M
Industry RankSector Rank
PM (TTM) N/A
ROA -53.64%
ROE -57.81%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%96.2%
Sales Q2Q%N/A
EPS 1Y (TTM)87.38%
Revenue 1Y (TTM)N/A

BBLG Ownership

Ownership
Inst Owners3.2%
Shares1.80M
Float1.79M
Ins Owners0.04%
Short Float %1.7%
Short Ratio1.03

About BBLG

Company Profile

BBLG logo image Bone Biologics Corp. operates as a medical device company. The company is headquartered in Burlington, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2015-11-27. The firm is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.

Company Info

IPO: 2015-11-27

BONE BIOLOGICS CORP

2 Burlington Woods Dr Ste 100

Burlington MASSACHUSETTS US

Employees: 2

BBLG Company Website

BBLG Investor Relations

Phone: 17815524452

BONE BIOLOGICS CORP / BBLG FAQ

Can you describe the business of BONE BIOLOGICS CORP?

Bone Biologics Corp. operates as a medical device company. The company is headquartered in Burlington, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2015-11-27. The firm is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.


Can you provide the latest stock price for BONE BIOLOGICS CORP?

The current stock price of BBLG is 1.16 USD.


Does BBLG stock pay dividends?

BBLG does not pay a dividend.


How is the ChartMill rating for BONE BIOLOGICS CORP?

BBLG has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Where is BONE BIOLOGICS CORP (BBLG) stock traded?

BBLG stock is listed on the Nasdaq exchange.


Can you provide the sector and industry classification for BONE BIOLOGICS CORP?

BONE BIOLOGICS CORP (BBLG) operates in the Health Care sector and the Biotechnology industry.


What is the outstanding short interest for BONE BIOLOGICS CORP?

The outstanding short interest for BONE BIOLOGICS CORP (BBLG) is 1.7% of its float.